Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 04, 2015 1:42 PM ET

Healthcare Equipment and Supplies

Company Overview of Pulmonx Inc

Company Overview

Pulmonx Inc. engages in designing, developing, manufacturing, and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. It offers Chartis Pulmonary Assessment System, which helps pulmonologists with lobe-specific information about a patient’s lung, and enables them to plan valve treatments to account for anatomical variations in the lungs of individual patients; and Zephyr Endobronchial Valve (EBV), a diagnostic and therapeutic solution to predict and achieve reduction of volume in the diseased portion of the lung without the risks and complications of surgery. The company’s products are used to deliver endoscopic lung volume re...

700 Chesapeake Drive

Redwood City, CA 94063

United States

Founded in 1998





Key Executives for Pulmonx Inc

Chief Executive Officer, President and Director
Age: 53
Founder and Chairman
Vice President of Finance and Administration
Age: 55
Executive Vice President and General Manager
Compensation as of Fiscal Year 2015.

Pulmonx Inc Key Developments

Pulmonx Announces the Lancet of Results from the BeLieVeR-HIFi clinical trial

Pulmonx announced the publication in the Lancet of results from the BeLieVeR-HIFi clinical trial. BeLieVeR-HIFi is a prospective, double-blind, randomized, sham-controlled trial comparing use of Pulmonx’s minimally invasive valve treatment for severe emphysema patients – the Zephyr Endobronchial Valve – to a sham bronchoscopy procedure. The study exceeded its primary endpoint, demonstrating a 20.9% average improvement in lung function (FEV1) in treated patients compared to control patients. Clinical and statistical significance on several secondary endpoints was also demonstrated, including exercise capacity and gas trapping. There was no statistical difference between groups in safety.

Pulmonx Corporation Announces Appointment of Glen French as President, Chief Executive Officer and Member of the Board of Directors

Pulmonx Corporation announced that appointment of Glen French as President, Chief Executive Officer and member of the Board of Directors. Most recently, he was CEO of ApniCure. Prior to ApniCure, Mr. French was Co-Founder, President and CEO of Asthmatx. At Asthmatx, he was responsible for guiding the company through clinical testing, FDA PMA approval, manufacturing expansion, initial product launch and acquisition by Boston Scientific Corporation. Following the acquisition, Mr. French served as President, Pulmonary Endoscopy for Boston Scientific's Endoscopy Division.

Similar Private Companies By Industry

Company Name Region
Health Sonics Corporation United States
CAVU Medical, Inc. United States
Titan Spine, LLC United States
RadioMed Corporation United States
First Check Diagnostics Corp. United States

Recent Private Companies Transactions

January 8, 2015
Aeris Therapeutics, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Pulmonx Inc, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at